This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020. https://doi.org/10.1038/s41375-019-0700-9.
Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016;3:e581–91.
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112:3965–73.
Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, et al. Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. Blood Adv. 2019;3:312–9.
Acknowledgements
AEE would like to thank his mentor retired Prof. Teoman Soysal for his continuous support and guidance and he wishes him a long, happy, and healthy retirement.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
AEE has received advisory board honorarium from Novartis, and he also received speaker bureau honoraria from Novartis, Bristol-Myers Squibb, and Pfizer outside the present study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Eşkazan, A.E. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. Leukemia 34, 3426–3427 (2020). https://doi.org/10.1038/s41375-020-0796-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0796-y